Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Study of Human Orexin-1 and -2 G-Protein-Coupled Receptors with Novel and Published Antagonists by Modeling, Molecular Dynamics Simulations, and Site-Directed Mutagenesis
Alexander Heifetz, G. Benjamin Morris, Philip C. Biggin, et al.
Biochemistry (2012) Vol. 51, Iss. 15, pp. 3178-3197
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Physiology of the orexinergic/hypocretinergic system: a revisit in 2012
Jyrki P. Kukkonen
AJP Cell Physiology (2012) Vol. 304, Iss. 1, pp. C2-C32
Closed Access | Times Cited: 133
Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors
Jie Yin, Kerim Babaoglu, Chad A. Brautigam, et al.
Nature Structural & Molecular Biology (2016) Vol. 23, Iss. 4, pp. 293-299
Closed Access | Times Cited: 132
Selective orexin receptor antagonists
Terry P. Lebold, Pascal Bonaventure, Brock T. Shireman
Bioorganic & Medicinal Chemistry Letters (2013) Vol. 23, Iss. 17, pp. 4761-4769
Closed Access | Times Cited: 73
Crystal Structures of Human Orexin 2 Receptor Bound to the Subtype-Selective Antagonist EMPA
Ryoji Suno, Kanako Kimura, Takanori Nakane, et al.
Structure (2017) Vol. 26, Iss. 1, pp. 7-19.e5
Open Access | Times Cited: 66
OX1 and OX2 orexin/hypocretin receptor pharmacogenetics
Miles D. Thompson, Henri Xhaard, Takeshi Sakurai, et al.
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 61
Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?
Shaun Yon‐Seng Khoo, Robyn M. Brown
CNS Drugs (2014) Vol. 28, Iss. 8, pp. 713-730
Open Access | Times Cited: 58
Therapeutics development for addiction: Orexin-1 receptor antagonists
David A. Perrey, Yanan Zhang
Brain Research (2018) Vol. 1731, pp. 145922-145922
Open Access | Times Cited: 55
The Orexin receptors: Structural and anti-tumoral properties
Alain Couvineau, Pascal Nicole, Valérie Gratio, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 20
Toward an Understanding of Agonist Binding to Human Orexin-1 and Orexin-2 Receptors with G-Protein-Coupled Receptor Modeling and Site-Directed Mutagenesis
Alexander Heifetz, Oliver Barker, G. Benjamin Morris, et al.
Biochemistry (2013) Vol. 52, Iss. 46, pp. 8246-8260
Open Access | Times Cited: 42
Characterization of the dynamic events of GPCRs by automated computational simulations
Hugo Gutiérrez‐de‐Terán, Xabier Bello, David Rodríguez
Biochemical Society Transactions (2013) Vol. 41, Iss. 1, pp. 205-212
Closed Access | Times Cited: 41
Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics
Miles D. Thompson, Takeshi Sakurai, Innocenzo Rainero, et al.
Pharmaceuticals (2017) Vol. 10, Iss. 4, pp. 79-79
Open Access | Times Cited: 35
GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014
Alexander Heifetz, Gebhard F. X. Schertler, Roland Seifert, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2015) Vol. 388, Iss. 8, pp. 883-903
Open Access | Times Cited: 34
Using the fragment molecular orbital method to investigate agonist–orexin-2 receptor interactions
Alexander Heifetz, Matteo Aldeghi, Ewa I. Chudyk, et al.
Biochemical Society Transactions (2016) Vol. 44, Iss. 2, pp. 574-581
Open Access | Times Cited: 32
Guiding lead optimization with GPCR structure modeling and molecular dynamics
Alexander Heifetz, Tim James, Iñaki Morao, et al.
Current Opinion in Pharmacology (2016) Vol. 30, pp. 14-21
Open Access | Times Cited: 30
Unraveling the function and structure impact of deleterious missense SNPs in the human OX1R receptor by computational analysis
Mahvash Farajzadeh-Dehkordi, Ladan Mafakher, Abbas Harifi, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Mapping histamine H4receptor–ligand binding modes
Sabine Schultes, Saskia Nijmeijer, Harald Engelhardt, et al.
MedChemComm (2012) Vol. 4, Iss. 1, pp. 193-204
Closed Access | Times Cited: 26
Elucidation of Conformational States, Dynamics, and Mechanism of Binding in Human κ-Opioid Receptor Complexes
Georgios Leonis, Aggelos Avramopoulos, Ramin Ekhteiari Salmas, et al.
Journal of Chemical Information and Modeling (2014) Vol. 54, Iss. 8, pp. 2294-2308
Closed Access | Times Cited: 24
Fighting Obesity with a Sugar-Based Library: Discovery of Novel MCH-1R Antagonists by a New Computational–VAST Approach for Exploration of GPCR Binding Sites
Alexander Heifetz, Oliver Barker, Géraldine Verquin, et al.
Journal of Chemical Information and Modeling (2013) Vol. 53, Iss. 5, pp. 1084-1099
Closed Access | Times Cited: 23
Computational Methods Used in Hit-to-Lead and Lead Optimization Stages of Structure-Based Drug Discovery
Alexander Heifetz, Michelle Southey, Iñaki Morao, et al.
Methods in molecular biology (2017), pp. 375-394
Closed Access | Times Cited: 21
Mutagenesis and Computational Modeling of Human G-Protein-Coupled Receptor Y2 for Neuropeptide Y and Peptide YY
Bo Xu, Helena Fällmar, Lars Boukharta, et al.
Biochemistry (2013) Vol. 52, Iss. 45, pp. 7987-7998
Closed Access | Times Cited: 22
Neuropeptide receptors as potential pharmacological targets for obesity
Beatriz T. Meneguetti, Marlon H. Cardoso, Camila Fontoura Acosta Ribeiro, et al.
Pharmacology & Therapeutics (2018) Vol. 196, pp. 59-78
Closed Access | Times Cited: 20
Pharmacophore Model To Discover OX1 and OX2 Orexin Receptor Ligands
Ainoleena Turku, Alexandre Borrel, Teppo O. Leino, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 18, pp. 8263-8275
Closed Access | Times Cited: 19
Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold‐Hopping Approach
Bibia Heidmann, John Gatfield, Catherine Roch, et al.
ChemMedChem (2016) Vol. 11, Iss. 19, pp. 2132-2146
Closed Access | Times Cited: 17
Molecular basis of agonist docking in a human GPR103 homology model by site‐directed mutagenesis and structure–activity relationship studies
Cédric Neveu, Fabienne Dulin, Benjamin Lefranc, et al.
British Journal of Pharmacology (2014) Vol. 171, Iss. 19, pp. 4425-4439
Open Access | Times Cited: 13
Application of an Integrated GPCR SAR-Modeling Platform To Explain the Activation Selectivity of Human 5-HT2C over 5-HT2B
Alexander Heifetz, Richard Storer, Gordon McMurray, et al.
ACS Chemical Biology (2016) Vol. 11, Iss. 5, pp. 1372-1382
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top